Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma. (Q38370539)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25751647%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

review article

1 reference

title

Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25751647%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25751647%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

author name string

N Lendvai

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25751647%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

H J Cho

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25751647%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

language of work or name

English

0 references

publication date

9 March 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25751647%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

2 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25751647%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

volume

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25751647%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25751647%20AND%20SRC:MED&resulttype=core&format=json

2 March 2020

page(s)

770-780

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25751647%20AND%20SRC:MED&resulttype=core&format=json

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

2 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Allogeneic hematopoietic cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Vigorous premalignancy-specific effector T cell response in the bone marrow of patients with monoclonal gammopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

T cells from the tumor microenvironment of patients with progressive myeloma can generate strong, tumor-specific cytolytic responses to autologous, tumor-loaded dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Therapeutic antitumor efficacy of anti-CD137 agonistic monoclonal antibody in mouse models of myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Induced sensitization of tumor stroma leads to eradication of established cancer by T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

CTLA-4: new insights into its biological function and use in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Enhancement of tumor-reactive cytotoxic CD4+ T cell responses after ipilimumab treatment in four advanced melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Immunologic correlates of the abscopal effect in a patient with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Immune checkpoint blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Immunosuppressive effects of multiple myeloma are overcome by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Programmed death receptor-1/programmed death receptor ligand-1 blockade after transient lymphodepletion to treat myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Heteroclitic immunization induces tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Identification of new epitopes from four different tumor-associated antigens: recognition of naturally processed epitopes correlates with HLA-A*0201-binding affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Structural features of peptide analogs of human histocompatibility leukocyte antigen class I epitopes that are more potent and immunogenic than wild-type peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

WT1-specific T-cell responses in high-risk multiple myeloma patients undergoing allogeneic T cell-depleted hematopoietic stem cell transplantation and donor lymphocyte infusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Myeloid-derived suppressor cells regulate growth of multiple myeloma by inhibiting T cells in bone marrow.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Donor killer cell Ig-like receptor B haplotypes, recipient HLA-C1, and HLA-C mismatch enhance the clinical benefit of unrelated transplantation for acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Infusion of haplo-identical killer immunoglobulin-like receptor ligand mismatched NK cells for relapsed myeloma in the setting of autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Highly activated and expanded natural killer cells for multiple myeloma immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Good manufacturing practice-compliant cell sorting and large-scale expansion of single KIR-positive alloreactive human natural killer cells for multiple infusions to leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Chimeric antigen receptor therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Chimeric antigen receptor T cells for sustained remissions in leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis Y antigen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

A molecular compendium of genes expressed in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Characterization of clonogenic multiple myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Stemness of B-cell progenitors in multiple myeloma bone marrow

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Salvage second hematopoietic cell transplantation in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2015.5

Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma--a feasibility study

21 January 2018

1 reference

12 December 2020

Synthetic peptide analogs derived from bcr/abl fusion proteins and the induction of heteroclitic human T-cell responses.

1 reference

12 December 2020

CD8+ T cells specific for cancer germline gene antigens are found in many patients with multiple myeloma, and their frequency correlates with disease burden

1 reference

12 December 2020

Allogeneic bone marrow transplantation in multiple myeloma. European Group for Bone Marrow Transplantation

1 reference

12 December 2020

Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation

1 reference

12 December 2020

Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors

1 reference

12 December 2020

T-cell immunotherapy with a chimeric receptor against CD38 is effective in eliminating myeloma cells

1 reference

12 December 2020

Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome

1 reference

12 December 2020

Phase I/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients

1 reference

12 December 2020

T-cell-depleted autologous bone marrow transplantation therapy: analysis of immune deficiency and late complications

1 reference

12 December 2020

In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chain

1 reference

12 December 2020

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor

1 reference

12 December 2020

Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma

1 reference

12 December 2020

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

12 December 2020

Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy

1 reference

12 December 2020

Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues

1 reference

12 December 2020